FIGO 2018宫颈癌分期标准对分期迁移和生存的影响
基于1282例宫颈癌患者队列,比较FIGO 2009与2018分期标准。53%患者出现分期上调,主要因检出隐匿性淋巴结转移(41%)和远处转移(7%)。FIGO 2018改善了I期和IV期患者的生存区分度,但III期各亚期生存仍不均。
要点
- FIGO 2018分期导致53%患者分期上调,无降期病例。
- 分期迁移主要归因于隐匿性淋巴结转移(41%)和远处转移(7%)。
- FIGO 2018改善了I期和IV期患者的生存区分度。
核心结论
- 纳入手术病理和影像学发现导致多数患者分期上调,主要与淋巴结和远处转移相关。
- FIGO 2018提高了I期和IV期患者的生存区分能力,但III期各亚期生存仍存在异质性。
研究设计与样本
- 基于1997至2019年1282例新诊断宫颈癌患者的数据库队列研究。
- 所有患者接受标准临床检查和全身FDG-PET,先按FIGO 2009分期,再重新分类为FIGO 2018分期。
主要发现
- FIGO 2009分期分布:I期593例(46%),II期342例(27%),III期263例(21%),IV期84例(7%)。
- FIGO 2018分期分布:I期354例(28%),II期156例(12%),III期601例(47%),IV期171例(13%)。
- 分期迁移发生率为53%(676/1282),归因于隐匿性淋巴结转移520例(41%)、隐匿性远处转移90例(7%)和肿瘤大小及范围66例(5%)。
- 5年无进展生存率(PFS)FIGO 2009 vs FIGO 2018:I期80% vs 87%(p=0.02);II期59% vs 71%(p=0.002);III期35% vs 55%(p<0.001);IV期20% vs 16%(p=0.41)。
关键数值与推荐
- FIGO 2009分期排除手术病理、FDG-PET及其他先进影像学发现,FIGO 2018分期纳入手术病理和影像学发现。
临床怎么用
- 临床分期时应纳入手术病理和影像学发现以准确评估病情。
- 对于FIGO 2018 III期患者,需注意各亚期生存异质性,个体化评估预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare FIGO 2009 and FIGO 2018 cervical cancer staging criteria with a focus on stage migration and treatment outcomes. METHODS: This study is based on a database cohort of 1282 patients newly diagnosed with cervical cancer from 1997 to 2019. All underwent standard clinical examination and whole-body FDG-PET. Tumor stage was recorded using the FIGO 2009 system, which excluded surgical pathologic, FDG-PET and other advanced imaging findings, and then re-classified to the FIGO 2018 system, including surgical pathologic and imaging findings. Patient management was based on clinical, surgical, and imaging findings. Stage migration and prognosis were evaluated. RESULTS: The distribution per the 2009 staging system was stage I in 593 (46%), stage II in 342 (27%), stage III in 263 (21%), and stage IV in 84 (7%) and the 2018 staging system was stage I in 354 (28%), stage II in 156 (12%), stage III in 601 (47%), and stage IV in 171 (13%). No patients were down-staged. Stage migration occurred in 53% (676/1282) and was attributable to detection of occult lymph node metastasis in 520 (41%), occult distant metastasis in 90 (7%), and tumor size and extent in 66 (5%). The 5-year progression-free survivals (PFS) by FIGO 2009 versus FIGO 2018 were as follows: stage I, 80% vs. 87% (p = 0.02); stage II, 59% vs. 71% (p = 0.002); stage III, 35% vs. 55% (p < 0.001), and stage IV, 20% vs. 16% (p = 0.41). CONCLUSION: Inclusion of surgical pathologic and imaging findings resulted in upward stage migration in the majority, mostly related to nodal and distant metastasis. While FIGO 2018 improves survival discriminatory ability for stages I and IV patients, survival remains heterogeneous among stage III substages.
引用
- Grigsby PW, Massad LS, Mutch DG, et al. FIGO 2018 staging criteria for cervical cancer: Impact on stage migration and survival. Gynecol Oncol. 2020. PMID: 32248993. doi:10.1016/j.ygyno.2020.03.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。